Avoid live vaccines in immunosuppressed patients, MHRA reminds clinicians

Healthcare professionals are warned to exclude the presence of significant immunosuppression before administering live attenuated vaccines, following reports of fatal infections in immunocompromised individuals.

Live vaccines include MMR, BCG and yellow fever. | iStock
Live vaccines include MMR, BCG and yellow fever. | iStock

Live attenuated vaccines should not routinely be given to people who are clinically immunosuppressed, whether due to drug treatment or underlying illness. Minor immunodeficiency does not necessarily contraindicate vaccination.

Further information
View vaccine drug records
MHRA Drug Safety Update
Green Book

If primary care professionals are in any doubt as to whether a person due to receive a live attenuated vaccine may be immunosuppressed, immunisation should be deferred until specialist advice has been sought, including from an immunologist if required.

Close contacts of immunosuppressed individuals should be fully immunised to minimise the risk of infection of vaccine-preventable diseases in immunosuppressed individuals.

The reports that prompted the MHRA's reminder included four neonates who died from disseminated BCG or tuberculosis infection after exposure to a TNF antagonist in utero. As a precaution, infants who have been exposed to immunosuppressive treatment from the mother either in utero during pregnancy or via breastfeeding should have any live attenuated vaccination deferred for as long as a postnatal influence on the immune status of the infant remains possible. In the case of in utero exposure to biological medicines, vaccination should not be considered until the child is at least 6 months old.

There were also reports of elderly patients receiving shingles vaccine (Zostavax) when they may have been immunosuppressed as a result of lymphoproliferative disorders or treatment for a transplant, and subsequently experiencing adverse reactions possibly associated with a disseminated viral infection caused by the vaccine strain.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases